

ASX ANNOUNCEMENT

19 November 2024

Results of Annual General Meeting

Melbourne, Australia; 19 November 2024: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises that its Annual General Meeting of Shareholders was held today at the Amora Hotel Riverwalk Melbourne, 649 Bridge Road, Richmond VIC 3121 at 10.00 am AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

Resolutions 1 to 5 were carried on a poll, with Resolution 3 (Approval of 10% Placement Facility) being carried by a sufficient majority as a special resolution.

Further information required by section 251AA(2) of the *Corporations Act 2001 (Cth)* is attached.

-ENDS-

Authorised for release by Dr Kilian Kelly, CEO & Managing Director

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, lauren@ittlebigdeal.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3 – patient enrolment completed) and diabetic foot ulcers (DFU – patient enrolment completed) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

Disclosure of Proxy Votes

Cynata Therapeutics Limited

Annual General Meeting
Tuesday, 19 November 2024



AUTOMIC
Automic

GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	62,548,535	59,410,831 94.98%	2,702,727 4.32%	244,017	434,977 0.70%	63,593,034 95.92%	2,702,727 4.08%	244,017	-
2 Re-election of Dr Paul Wotton as a Director	P	63,627,990	60,470,126 95.04%	2,722,449 4.28%	160,935	435,415 0.68%	64,702,767 95.96%	2,722,449 4.04%	160,935	Carried
3 Approval of 10% Placement Facility	P	63,577,964	61,129,384 96.15%	1,997,855 3.14%	210,961	450,725 0.71%	65,377,335 97.03%	1,997,855 2.97%	210,961	Carried
4 Ratification of the issue of the TekCyte Shares	P	62,926,612	62,267,774 98.95%	223,861 0.36%	862,313	434,977 0.69%	66,499,977 99.66%	223,861 0.34%	862,313	Carried
5 Ratification of the issue of the Corporate Adviser Options	P	63,329,122	60,785,012 95.98%	2,094,045 3.31%	459,803	450,065 0.71%	62,432,303 93.01%	4,694,045 6.99%	459,803	Carried

